Leading PE fund executed a successful deal by validating a 15% CAGR for 11 cytotoxic molecules
06 May 2020
1 min read
We studied the overall oncology & critical care market captured by domestic players. For our target company, we estimated the market share and its growth potential across 7 key countries and 11 key onco molecules
Context
- Client Description: A leading PE fund
- Opportunity: The client was interested in buying an Indian pharmaceutical company in the generic cytotoxic and oncology drug manufacturing space.
For the same purpose client wanted to:
- Understand key market growth drivers for 11 cytotoxic drug molecules and therefore estimate market growth in the next 5 years
- Understand pharma company’s potential business for the 11 molecules in Indian market and key differentiators compared to other players in the same space
Our Approach
- Conducted more than 100 focused discussions with oncologists, radiologists, pharmacists and purchase managers in major hospitals and cancer centers across
- Gathered data from published data sources, retail data, and other drug data to size demand for domestic markets
- Conducted several expert calls with top management in leading drug pharma players in the Indian market
- The estimated market size of each drug molecule in Indian as well as international markets from present market size obtained from management data and using information obtained from experts as well as own analysis